ARTV: Aslan Fred discloses a sale
By AlphaYouPublished Form 4
Aslan Fred
Reporting filer
Aslan Fred reported Sale in Artiva Biotherapeutics, Inc.: 61696 units of Common Stock, dated 2026-10-05. The full Form 4 contains 1 transaction entry.
- Disclosed
- Oct 6, 2026
Reported details
1 entry| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Aslan Fred | 2026-10-05 | S | Sale | 61696 | 6.8372 | 1,543,069 | 1 day | Filed terms
|
Common Stock
- Owner
- Aslan Fred
- Date
- 2026-10-05
- Code
- S
- Action
- Sale
- Quantity
- 61696
- Price
- 6.8372
- Following holdings
- 1,543,069
- Reporting delay
- 1 day
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-10-05
- transaction Form Type: 4
- transaction Code: S
- equity Swap Involved: false
- transaction Shares: 61696
- id: F1
- transaction Price Per Share: 6.8372
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 1543069
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Aslan Fred: Chief Executive Officer, Director.
- F1: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
Original sources
Prepared automatically from public filing data. Report a correction.